Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Lievens



Author of

  • +

    OA24 - Radiotherapy of Lung Cancer: Recent Developments (ID 411)

    • Event: WCLC 2016
    • Type: Oral Session
    • Track: Radiotherapy
    • Presentations: 1
    • +

      OA24.01 - Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial (ID 4274)

      14:20 - 15:50  |  Author(s): Y. Lievens

      • Abstract
      • Presentation
      • Slides

      Background:
      Trials of chemoradiotherapy for different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation quality assurance (RTQA) was mandated for all patients treated in the PROCLAIM (NCT00686959) trial evaluating two different chemoradiotherapy regimens.

      Methods:
      The study was open to accrual between 2008-2012. Planned chemoradiotherapy dose was 60-66 Gy in daily 2 Gy fractions. Quality was assessed through review of radiation treatment plans and monitoring of protocol violations. Review of the radiation plan was mandated for all patients; prior to radiation start for the first enrolled patient at each site. Real-time review was performed randomly in 20% of additional patients with nonreal-time review performed for the remainder. Parameters assessed for major violations per protocol included: <95% of planned total volume (PTV) received by 93% of prescribed dose; >1 cm[3] contiguous volume within or outside the PTV received >115% of prescribed dose; V~20~ (volume of lung receiving ≥20 Gy) >38%; and maximum point dose to spinal cord of >48 Gy. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kapan-Meier methodology and groups were compared by log-rank test and Cox proportional hazard modeling.

      Results:
      Of 598 patients randomized in 126 investigational sites, 554 received study assigned chemoradiotherapy. The median dose delivered was 66 Gy, with 92.6% of patients receiving planned chemoradiotherapy dose (60-66 Gy). A total of 40 patients, enrolled at twenty-eight sites had major RTQA violations. Seven sites enrolled ≥2 patients with major violations. Patients with major violations has a higher incidence of Stage IIIB disease (70.0% vs. 50.6%) and larger tumors (median planned PTV=653 vs. 523cc) than patients with no violations. Patients treated at sites with ≥2 patients with violations (n=86), had a lower median OS (median 21.1 vs. 29.8 months; HR 1.442) and median PFS (median 7.3 vs. 11.3 months; HR 1.345) than patients at sites where none had violations.

      Conclusion:
      Major chemoradiotherapy protocol violations were uncommon in the PROCLAIM study, which may be a reflection of the mandatory RTQA. Protocol violations were more frequent in patients with Stage IIIB and larger tumors, which generally require more complex chemoradiotherapy plans. The observation of discrepant outcomes at centres with multiple major RTQA violations is hypothesis-generating but should be interpreted with caution due to the small number of patients.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.05 - Poster Session with Presenters Present (ID 463)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Radiotherapy
    • Presentations: 1
    • +

      P2.05-017 - Tumor Regression Gradient Predicts Disease Free Survival (ID 5926)

      14:30 - 15:45  |  Author(s): Y. Lievens

      • Abstract

      Background:
      Tumor regression during chemoradiation (CRT) in stage III non-small cell lung cancer patients has been described. Our aim was to investigate whether the extent of the primary tumor shrinkage is associated with local control and survival.

      Methods:
      Changes in the volume of the primary tumor (GTV-T) of 41 patients treated with concurrent (cCRT) (n = 21) or sequential (sCRT) (n=20) CRT were analyzed using cone-beam CT (CBCT) at every fifth fraction (F5–F30). Only changes in the primary tumor (excluding the lymph nodes) were considered. Previous research revealed F15 and F20 as optimal timing for treatment adaptation for cCRT and sCRT respectively (Berkovic et al. Acta Oncol 2015). Local control and survival data were reviewed retrospectively. Impact of the tumor regression at the time of the optimal adaptation timing during treatment (higher or lower than median) and chemotherapy schedule (cCRT vs. sCRT) on local control and survival were evaluated using the Kaplan-Meier survival comparison (log-rank test, p<0.05 were considered significant).

      Results:
      Median local control (LC) and overall survival (OS) was 32.5 res. 29.9 months in the sCRT and 31.4 res. 23.3 months in the cCRT group. LC and OS did not differ significantly for the cCRT and sCRT cohort. The median GTV reduction was 35.0% (range 2.8–64.2%) at F15 for cCRT, while 21.9% (2.1-53.5%) at F20 for sCRT patients. Higher than the group median (for cCRT and sCRT) GTV-T reduction showed statistically significant impact only on disease specific survival (p=0.016, Figure 1).

      Conclusion:
      Higher gradient GTV-T reduction during RT significantly correlates with better disease specific survival. Additional tumor and patient characteristics should be studied in larger patient cohorts to further understand tumor behavior and to offer a validated predictive tool of therapeutic outcomes. Figure 1. Kaplan-Meier survival curve for DSS. Figure 1